Synteny

About Synteny

Synteny.ai is a cutting-edge startup focused on revolutionizing the healthcare industry by leveraging artificial intelligence (AI) to decode biological data and accelerate disease discovery. The company operates in the biotechnology and healthcare market, specifically targeting the intersection of immunology and data science. Synteny.ai's primary clients include pharmaceutical companies, research institutions, and healthcare providers who are looking to enhance their understanding of immune data to develop new treatments and therapies.

The core of Synteny.ai's business model is its AI platform, which is designed to analyze complex immune data to uncover insights that can lead to the discovery of new diseases and the development of innovative treatments. This platform integrates expertise from various fields, including computer science, immunology, mathematics, and engineering, to provide a comprehensive solution for its clients.

Synteny.ai generates revenue through a combination of subscription fees for access to its AI platform, consulting services, and partnerships with pharmaceutical companies and research institutions. By offering a robust and scalable AI solution, the company helps its clients accelerate their research and development processes, ultimately leading to faster and more effective disease treatments.

The leadership team at Synteny.ai includes co-founders Lilly Wollman (CEO) and Jamie Blundell (Chief Scientific Officer), along with a diverse group of experts such as Neil Dalchau (Chief Research Officer), Mike Stubbington (Biology and Data Generation), Aaron Sim (Machine Learning), and David Carter (Engineering). This world-class team is supported by an inspiring group of advisors who contribute to the company's growth and impact.

In summary, Synteny.ai is a pioneering startup that uses AI to decode immune data, serving pharmaceutical companies, research institutions, and healthcare providers. Its business model revolves around subscription fees, consulting services, and strategic partnerships, all aimed at accelerating disease discovery and treatment development.